These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33241960)

  • 1. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects.
    Wu M; Sun J; Wu D; Xu J; Wei J; Wang Z; Yu J; Li S; Zhang H; Ding Y
    Expert Opin Investig Drugs; 2021 Jan; 30(1):77-83. PubMed ID: 33241960
    [No Abstract]   [Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
    Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
    Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
    Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
    Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.
    Chow V; Oh M; Gessner MA; Fanjiang G
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx
    Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W
    Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
    Eto T; Karasuyama Y; González V; Del Campo García A
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
    Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W
    Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
    Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
    Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
    Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
    Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
    BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects.
    Tomaszewska-Kiecana M; Carapuça E; Florez-Igual A; Queiruga-Parada J
    Clin Transl Sci; 2024 Sep; 17(9):e70013. PubMed ID: 39206788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
    Gao X; Di Y; Lv Y; Luan Y; Xiong Y; Xu Y; Li Y; Guo L; Li X; Deng L; Zhuang Y; Hou J
    Clin Transl Sci; 2024 Apr; 17(4):e13775. PubMed ID: 38651744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.